Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 50

1.

TPD52 expression increases neutral lipid storage within cultured cells.

Kamili A, Roslan N, Frost S, Cantrill LC, Wang D, Della-Franca A, Bright RK, Groblewski GE, Straub BK, Hoy AJ, Chen Y, Byrne JA.

J Cell Sci. 2015 Jul 16. pii: jcs.167692. [Epub ahead of print]

PMID:
26183179
2.

Overexpressed oncogenic tumor-self antigens.

Bright RK, Bright JD, Byrne JA.

Hum Vaccin Immunother. 2014;10(11):3297-305. doi: 10.4161/hv.29475.

PMID:
25483660
3.

Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?

Byrne JA, Frost S, Chen Y, Bright RK.

Tumour Biol. 2014 Aug;35(8):7369-82. doi: 10.1007/s13277-014-2006-x. Epub 2014 May 6. Review.

PMID:
24798974
4.

Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen.

Bright JD, Schultz HN, Byrne JA, Bright RK.

Oncoimmunology. 2013 Jul 1;2(7):e25049. Epub 2013 May 21.

5.

TPD52 represents a survival factor in ERBB2-amplified breast cancer cells.

Roslan N, Bièche I, Bright RK, Lidereau R, Chen Y, Byrne JA.

Mol Carcinog. 2014 Oct;53(10):807-19. doi: 10.1002/mc.22038. Epub 2013 May 9.

PMID:
23661506
6.

A growing role for hypertrophy in senescence.

Wright J, Dungrawala H, Bright RK, Schneider BL.

FEMS Yeast Res. 2013 Feb;13(1):2-6. doi: 10.1111/1567-1364.12015. Epub 2012 Nov 23. No abstract available.

7.

The role of gamma interferon in DNA vaccine-induced tumor immunity targeting simian virus 40 large tumor antigen.

Aldrich JF, Shearer MH, Lowe DB, Winn RE, Jumper CA, Kennedy RC, Bright RK.

Cancer Immunol Immunother. 2013 Feb;62(2):371-82. doi: 10.1007/s00262-012-1338-x. Epub 2012 Aug 25.

PMID:
22926061
8.

CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.

Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Bright RK, Kennedy RC.

J Virol. 2011 Jul;85(14):7216-24. doi: 10.1128/JVI.00543-11. Epub 2011 May 18.

9.

Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.

Lowe DB, Shearer MH, Jumper CA, Bright RK, Kennedy RC.

J Virol. 2010 Jan;84(2):883-93. doi: 10.1128/JVI.01512-09. Epub 2009 Nov 4.

10.

Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.

Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK.

Cancer Immunol Immunother. 2009 Aug;58(8):1337-49. doi: 10.1007/s00262-009-0659-x. Epub 2009 Jan 24.

PMID:
19169682
11.

Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52.

Shehata M, Bièche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R, Byrne JA.

Clin Cancer Res. 2008 Aug 15;14(16):5050-60. doi: 10.1158/1078-0432.CCR-07-4994.

12.

Evidence of simian virus 40 exposure in a colony of captive baboons.

Westfall LW, Shearer MH, Jumper CA, White GL, Papin JF, Eberle R, Butel JS, Bright RK, Kennedy RC.

Virology. 2008 Jul 20;377(1):54-62. doi: 10.1016/j.virol.2008.03.035. Epub 2008 May 16.

13.

Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity.

Payton LA, Lewis JD, Byrne JA, Bright RK.

Cancer Immunol Immunother. 2008 Jun;57(6):799-811. Epub 2007 Oct 26.

PMID:
17962942
14.

Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52.

Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, Bright RK.

Mol Cancer Res. 2007 Feb;5(2):133-44.

15.
16.

Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases.

Lewis JD, Shearer MH, Kennedy RC, Bright RK.

Cancer Res. 2005 Apr 1;65(7):2938-46.

17.

In vitro simian virus 40 large tumor antigen expression correlates with differential immune responses following DNA immunization.

Lowe DB, Shearer MH, Tarbox JA, Kang HS, Jumper CA, Bright RK, Kennedy RC.

Virology. 2005 Feb 5;332(1):28-37.

18.

Cancer immunotherapy: avoiding the road to perdition.

Chiriva-Internati M, Grizzi F, Bright RK, Martin Kast W.

J Transl Med. 2004 Jul 29;2(1):26.

19.

Anti-idiotype responses abrogate anti-CD4-induced tolerance to a tumor-specific antigen and promote systemic tumor immunity.

Kennedy RC, Shearer MH, Lowe DB, Jumper CA, Chiriva-Internati M, Bright RK.

Cancer Immunol Immunother. 2004 Nov;53(11):987-94. Epub 2004 May 19.

PMID:
15156293
20.

Sperm protein 17 is expressed in human somatic ciliated epithelia.

Grizzi F, Chiriva-Internati M, Franceschini B, Bumm K, Colombo P, Ciccarelli M, Donetti E, Gagliano N, Hermonat PL, Bright RK, Gioia M, Dioguardi N, Kast WM.

J Histochem Cytochem. 2004 Apr;52(4):549-54.

PMID:
15034007
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk